5 citations
,
April 2019 in “Journal of Nepal Health Research Council” People with Alopecia areata often have lower vitamin D levels, which may be linked to the severity of their condition.
2 citations
,
January 2023 in “Dermatology Practical & Conceptual” AB+ blood group is more common in alopecia areata patients.
1 citations
,
December 2022 in “Journal of cosmetic dermatology” The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.
1 citations
,
March 2023 in “SKIN The Journal of Cutaneous Medicine”
March 2022 in “Nepal Journal of Dermatology Venereology & Leprology” Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.
July 2021 in “Dermatology archives” Methotrexate may effectively and safely treat hair loss in children, with notable improvement after 12-15 months.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
June 2024 in “JEADV Clinical Practice” Severe alopecia areata patients have a low chance of spontaneous hair regrowth.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
7 citations
,
July 2022 in “Quality of Life Research” 80% scalp hair regrowth is a successful treatment for alopecia areata.
January 2026 in “Dermatologic Therapy” Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
May 2024 in “JEADV Clinical Practice” A change in SALT scores of 42 or 43 indicates meaningful improvement in alopecia areata treatment.
December 2023 in “JEADV Clinical Practice” A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.
December 2023 in “International journal of research in dermatology” Adding PRP to topical mometasone improves and speeds up alopecia areata treatment.
28 citations
,
April 2017 in “Journal of cosmetic dermatology” Low vitamin D can worsen pediatric alopecia areata.
2 citations
,
January 2018 in “International journal of research in dermatology” Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.
Human placental extract effectively and safely improves melasma, ulcers, and alopecia areata.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
June 2024 in “British Journal of Dermatology” Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.
January 2025 in “Journal of Bacha Khan Medical College.” Double-spin PRP is more effective for treating male pattern baldness.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
1 citations
,
August 2024 in “British Journal of Dermatology” Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
April 2026 in “Dermatology and Therapy” Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.